Shares in Amarin (AMRN) popped 4% in Thursday’s after hours trading after the company presented encouraging data on Vascepa (icosapent ethyl) in patients with prior PCI [percutaneous coronary intervention] at the virtual Transcatheter Cardiovascular Therapeutics (TCT) Connect conference.The REDUCE-IT PCI analysis looked at 3,408 (41.7%) of patients enrolled in REDUCE-IT who had undergone a prior PCI.Compared with placebo, Vascepa significantly reduced primary composite first and total MACE (major adverse cardiovascular events) in post hoc exploratory analyses of patients with a history of PCI by 34% and 39%, respectively, and key secondary composite first hard MACE, comprised of heart attacks, stroke …read more
Source:: Yahoo Finance
